Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension

Journal of Hypertension

Volumn 22, Issue 9, 2004, Pages 1761-1768

  Watanabe, Kouki ^a,d   Komatsu, Jiroh ^a   Kurata, Makoto ^a   Inaba, Shinji ^a   Ikeda, Shuntaro ^a   Sueda, Shozo ^b   Suzuki, Jun ^b   Kohara, Katsuhiko ^c   Hamada, Mareomi ^a  

^a Uwajima City Hospital   (Japan)

^b Saiseikai Saijo Hospital   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Uwajima City Hospital   (Japan)

Author keywords

Cardiac sympathetic nervous function; Hypertension; Insulin resistance; Troglitazone

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; IODINE 123; TROGLITAZONE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STEADY STATE;

EID: 4344665720     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200409000-00021     Document Type: Article

References (36)

1. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989; 2:140S-146S.
2. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 1989; 14:177-183.
3. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Luscher TF, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29:1607-1614.
4. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-477.
5. Levy D, Garisson RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
6. Kuwahara T, Hamada M, Hiwada K. Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med 1998; 39:1486-1491.
7. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M, et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999; 17:1161-1168.
8. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157:2413-2446.
9. Miyagawa M, Kumano S, Sekiya M, Watanabe K, Akutsu H, Imachi T, et al. Thallium-201 myocardial tomography with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease. J Am Coll Cardiol 1995; 26:1196-1201.
10. Freidwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
11. Harano Y, Hidaka H, Takatsuki K, Ohgaku S, Haneda M, Motoi S, et al. Glucose, insulin, and somatostatin infusion for the determination of insulin sensitivity in vivo. Metabolism 1978; 27 (suppl I):1449-1452.
12. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55:613-618.
13. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331:1188-1193.
14. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320.
15. 2+ currents and not endothelial nitric oxide production. Diabetes 1997; 46:659-664.
16. Hattori Y, Hattori S, Kasai K. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1999; 33:943-948.
17. Graf K, Xi XP, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett 1997; 400:119-121.
18. Santure M, Pitre M, Nadeau A, Bachelard H. Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats. Metabolism 2003; 52:978-986.
19. Stakos DA, Shuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. J Cardiol 2003; 41:183-190.
20. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients: troglitazone study group. Diabetologia 1996; 39:701-709.
21. Sunayama S, Watanabe Y, Ohmura H, Sawano M, Shimada M, Shimada K, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999; 146:187-193.
22. Kobayashi J, Nagashima I, Hikita M, Bujo H, Takahashi K, Otabe M, et al. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 1999; 47:433-439.
23. Nozue T, Michishita I, Minagawa F, Genda A. Troglitazone directly increases HDL cholesterol levels. Diabetes Care 1999; 22:355-356.
24. Sasson Z, Rasooly Y, Bhesania T, Rasooly I. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation 1993; 88:1431-1436.
25. Tobes MC, Jaques S, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenrylguanidine, J Nucl Med 1985; 26:897-907.
26. Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 1993; 22:292-299.
27. Nishio E, Watanabe Y. Troglitazone inhibites alpha 1-adrenoceptor-induced DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1999; 374:127-135.
28. de Dios ST, Hannan KM, Dilley RJ, Hill MA, Little PJ. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complic 2001; 15:120-127.
29. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97:996-1001.
30. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98:1897-1905.
31. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543-546.
32. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45:988-991.
33. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21:1470-1474.
34. Shek EW, Brands MW, Hall JE. Chronic leptin increases arterial pressure. Hypertension 1998; 31:409-414.
35. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984; 311:819-823.
36. Perry U, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG. Sodium insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 1996; 144:224-234.